For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Scholar Rock, Inc.

USPTO Granted Patents = 33

EPO Patents = 13

Trademarks = 1

Forward Citations = 214

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Michelle Marie Straub (21 out of 21 patents)

Thomas Schurpf (19 out of 19 patents)

Nagesh K Mahanthappa (14 out of 21 patents)

4. Justin W Jackson (12 out of 12 patents)

5. Stefan Wawersik (10 out of 10 patents)

6. Abhishek Datta (9 out of 9 patents)

7. Adriana Donovan (9 out of 12 patents)

8. Gregory John Carven (9 out of 19 patents)

9. Katherine Jane Turner (8 out of 16 patents)

10. Christopher Littlefield (7 out of 7 patents)

11. Caitlin Stein (6 out of 7 patents)

12. Matthew Salotto (6 out of 6 patents)

13. Dong Yun Lee (4 out of 4 patents)

14. Allan Capili (4 out of 4 patents)

15. Kevin B Dagbay (4 out of 4 patents)

33 patents: Sort by Forward Citations

1. 12661400 - Methods of Treating Myopathies with Anti-Pro/Latent Myostatin Antibodies (2026-06-23),

2. 12582712 - Method of Making Anti-Pro/Latent Myostatin Antibodies (2026-03-24),

3. 12577296 - Compositions and methods for growth factor modulation (2026-03-17),

4. 12454570 - Compositions and methods for growth factor modulation (2025-10-28),

5. 12358992 - LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof (2025-07-15),

6. 12338279 - Selective and potent inhibitory antibodies of myostatin activation (2025-06-24),

7. 12297262 - RGMC-selective inhibitors and use thereof (2025-05-13),

8. 12281159 - TGFβ antibodies, methods and uses (2025-04-21),

9. 12252531 - Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors (2025-03-18),

10. 12173059 - LTBP complex-specific inhibitors of TGFβ and uses thereof (2024-12-24),

11. 12122823 - Isoform-selective TGFB1 inhibitors and use thereof (2024-10-22),

12. 12006359 - Methods for altering body composition by administering anti-pro/latent myostatin antibodies (2024-06-11),

13. 11925683 - Compositions for making and using anti-Myostatin antibodies (2024-03-12),

14. 11827698 - Compositions and methods for growth factor modulation (2023-11-28),

15. 11643459 - TGFβ1-binding immunoglobulins and use thereof (2023-05-09),

Scholar Rock is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines to treat serious diseases. With their proprietary platform, they target the activation of TGF-beta for therapeutic purposes. They aim to bring transformative therapies to patients with a focus on diseases driven by fibrosis, immuno-oncology, and neuromuscular disorders. Scholar Rock's commitment to scientific excellence and patient-centric approach drives their efforts to advance novel therapies and address unmet medical needs.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Scholar Rock, Inc.

33 Patents

#88 in Cambridge, MA

#616 in Massachusetts

#10,288 in US

#20,112 in the World

Cambridge, MA, United States of America

Scholar Rock, Inc.

Forward Citations = 214

45 inventors:

Michelle Marie Straub (21 out of 21 patents)

Thomas Schurpf (19 out of 19 patents)

Nagesh K Mahanthappa (14 out of 21 patents)

4. Justin W Jackson (12 out of 12 patents)

5. Stefan Wawersik (10 out of 10 patents)

Please report any incorrect information to [email protected]

Loading…